Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Dyslipidemia Clinical Trials

A listing of Dyslipidemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (17) clinical trials

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease.


Clinical study of an investigational drug for subjects with high cholesterol who are on some cholesterol lowering medications. (Statins) The investigational product or placebo will be administered with an auto injector (pre-filled pen). This study is a 12 week treatment period with up to 9 visits to our office in ...


Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes

This is a phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes. In YH14755 treatment group, 88 subjects will be assigned and the subjects administer YH14755 for 16 weeks. In Metformin treatment group, 88 subjects will be assigned and the ...


Clinical Trial to Evaluate the Efficacy and Safety of Pravafenix Cap to Verify the Superiority Than Atorvastatin

This study is to Evaluate the Efficacy and Safety of Pravastatin/Fenofibrate Complex in Patients With Combined Dyslipidemia With Adequately Controlled LDL-C But Inadequately Controlled Triglyceride Level by Atorvastatin Monotherapy. After administrating the atorvastatin or Pravafenix Cap. (pravastatin sodium/fenofibrate) for 8 weeks, evaluate the variation of the Non-HDL-C for each arm. ...


Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).

A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).


Safety Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia

LDL-C = low density lipoprotein cholesterol QM = once monthly Double blind = neither the subject, the site staff nor the Sponsor study team will know whether the subject is receiving either evolocumab or placebo Open label = all subjects receive evolocumab


Cardioprotective Effects of Green Tea Versus Mat Intake

Recommendations of lifestyle and dietary content changes are often made for primary prevention and improvement of many health conditions, including cardiovascular disease. For centuries, green tea (Camellia sinensis) has been linked to good health. Nowadays, it is considered a functional food because of its physiological benefits, mainly in terms of ...